此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

氯沙坦和社会加工

2026年9月23日 更新者:University of Oxford

单剂量氯沙坦对健康成人社会加工的影响:一项随机对照研究

This study explores the effects of single-dose losartan (50mg) versus placebo on social processing in healthy volunteers.

研究概览

详细说明

While renin-angiotensin mechanisms have been implicated in physiological disease, such as hypertension and stroke, the discovery of a local brain renin-angiotensin system (RAS) in the 1970s brought into question whether the RAS may play a role in psychiatric disorders too. Recent work has supported this link, with several studies reporting RAS influence on aversive learning, stress response to traumatic stimuli, and fear extinction.

Despite these promising results, studies have yet to fully explore the influence of the RAS and losartan on social processes. It is plausible that the RAS may be involved in social functioning, as recent work reported that losartan reduces sensitivity to social punishment in healthy volunteers. Such an effect of losartan may have broad relevance for psychopathology, as impairment to social functioning is present across a range of psychiatric disorders.

In this double-blind, randomized between-group study, the investigators will examine the effects of a single dose of losartan (50mg) versus placebo on social processing in N=68 healthy volunteers. Following a one-hour waiting period, participants will complete a set of computer tasks investigating social processes reported to be sensitive to psychopathology. Specifically, participants will complete the Approach Avoidance Task which assesses social approach and avoidance behaviour in response to various facial expressions via joystick movement, the Interpretation Inflexibility Task which evaluates cognitive flexibility in a social context, the Social Learning Trust Game which evaluates social learning through a trust game between participant investors and realistic trustees, and Cyberball, which probes response to social rejection. Results from this study will provide more insight on the potential role of the RAS in social cognitive processing in humans, which could lead to an improved mechanistic understanding of emotional disorders that are marked by social impairment.

研究类型

介入性

注册 (实际的)

68

阶段

  • 第一阶段早期

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Oxfordshire
      • Oxford、Oxfordshire、英国、OX37JX
        • Warneford Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Willing and able to provide informed consent
  • Aged 18-50 years
  • Sufficient written and spoken English skills to understand what the study involves, and to complete the questionnaires
  • Non- or light-smoker (5 cigarettes a day, if vaping: less than 50 puffs)
  • BMI between 18 - 30

Exclusion Criteria:

  • Current DSM-5 axis-I diagnosis (based on SCID results at screening) or history of a severe psychological disorder such as psychotic disorder, bipolar disorder, alcohol or substance abuse, or post-traumatic stress disorder
  • First-degree family member with severe psychiatric illness (including psychosis, bipolar disorder, unipolar psychotic depression).
  • CNS-medication last 6 weeks (including as part of another study)
  • Current blood pressure or other heart medication, including aliskiren and beta blockers)
  • Diagnosis of intravascular fluid depletion or dehydration
  • History of angioedema
  • Impaired kidney function (based on self-report)
  • Very low blood pressure (defined as repeated (at least three consecutive measurements) measures of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90/50 mmHg (in accordance with established standard definitions)
  • Lifetime history of epilepsy or other neurological disorder, as established by a professional diagnosis (e.g. autism, ADHD)
  • Lifetime history of systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study
  • Significant loss of hearing that is not corrected with a hearing device
  • Women: pregnancy (as determined by a urine test, if the participant's pregnancy status is unknown during the in-person visit), breast-feeding

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Losartan

50 mg single-dose losartan

Single dose losartan (50 mg), encapsulated identically to placebo.

其他名称:
  • 科素亚
  • 氯沙坦
安慰剂比较:Placebo

Microcellulose placebo in identical capsule

Single tablet encapsulated identically to placebo.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
AAT effect score
大体时间:1 hour after capsule intake

mean reaction time of the pull trials of a valence category subtracted from the push trials of the same category, yielding a single indicator of approach/avoidance, with positive scores indicating relatively stronger approach and negative scores indicating relatively stronger avoidance

1 hour after capsule intake

次要结果测量

结果测量
措施说明
大体时间
Sensitivity to Social Rejection
大体时间:1 hour after capsule intake

a) feelings of belonging, control, self-esteem, meaningful existence (on a scale from 1 to 5, with some items reverse coded) as measured on the reflexive and reflective needs-threat scale following Cyberball.

1 hour after capsule intake
Social Learning
大体时间:1 hour after capsule intake

Social learning rate (early round versus late round investment decisions by generosity condition)

1 hour after capsule intake
Interpretation Inflexibility
大体时间:1 hour after capsule intake

Within-person revision of biased interpretations: calculated by taking the average of differences between bias scores between stage 3/2 and 2/1. These two differences will be squared before averaging to reflect absolute change (i.e., in either direction), then the square root of the resulting average will be taken. Higher values mean more flexibility in revising prior interpretations.

1 hour after capsule intake

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年8月19日

初级完成 (实际的)

2025年10月1日

研究完成 (实际的)

2025年10月1日

研究注册日期

首次提交

2024年9月23日

首先提交符合 QC 标准的

2024年9月30日

首次发布 (实际的)

2024年10月3日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2024年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅